Item 8.01. Other Events.

On March 16, 2023, Titan Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that it is no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed companies to maintain a minimum bid price of $1.00 per share. The letter noted that the bid price of the Company's common stock was below $1.00 for the 30-day period ending March 15, 2023.

The notification letter has no immediate effect on the Company's listing on the Nasdaq Capital Market. Nasdaq has provided the Company with 180 days, or until September 12, 2023, to regain compliance with the minimum bid price requirement by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

Item 9.01. Financial Statements and Exhibits.





(d)    Exhibits



Exhibit No.   Description
    104       Cover Page Interactive Data (embedded within the Inline XBRL document).




                                       1

© Edgar Online, source Glimpses